ClinicalTrialsFinder

Potentially Resectable Clinical Trials in Seoul, Seoul

1 recruitingSeoul, Seoul, South Korea

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC
Yonsei University39 enrolled1 locationNCT03694236